NASDAQ: HBIO Q4'22 Earnings Presentation The non-GAAP financial information provided in this presentation should be considered in addition to, not as a substitute for, the financial information provided and presented in accordance with GAAP and may be different than other companies' non-GAAP financial information. 3 "Organizational restructuring complete and setup for success in 2023!" Q4 New Product Launches Drive Growth, Expand Financial Section 7 For FY2023, we expect: ▪ Reduce debt leverage to ~ 2X leve ...

HBIO Overview to Investors NASDAQ: HBIO Q3'22 Earnings Presentation Jim Green, Chairman, President & CEO Mike Rossi, CFO November 8, 2022 HB Forward-Looking Statements and Non-GAAP Financial Information Forward-Looking Statements Information in this presentation or in oral statements of the management of the Company may include forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. You can identify these statements by our ...

Harvard Bioscience, Inc. (NASDAQ:HBIO) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants David Sirois - Director, Corporate Accounting & SEC Reporting James Green - President, CEO & Chairman Michael Rossi - CFO Conference Call Participants Paul Knight - KeyBanc Capital Markets Bruce Jackson - The Benchmark Company Operator Good day, and thank you for standing by. Welcome to the Harvard Bioscience Third Quarter 2022 Earnings Call. [Operator Instructions]. Please be advised tha ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (State or other jurisdiction of Incorporation or organization) (I.R.S. Employer Identification No.) 84 October Hill Road, Holliston, Massachusetts 01746 (Address of Principal Executive Offices, including zip code) ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2022 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange ...

Harvard Bioscience, Inc. (NASDAQ:HBIO) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants David Sirois - Director of Corporate Accounting & SEC Reporting Jim Green - President & Chief Executive Officer Mike Rossi - Chief Financial Officer Conference Call Participants Bruce Jackson - The Benchmark Company Paul Knight - KeyBanc Capital Markets Operator Good day, and thank you for standing by. Welcome to the Q2 2022 Harvard Bioscience, Inc. Earnings Conference Call. [Operator Instr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2022 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ____to _____ (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: | Title of each class | Trading Symbol(s) | Name ...

NASDAQ: HBIO Q2'22 Earnings Presentation Jim Green, Chairman, President & CEO Mike Rossi, CFO August 4, 2022 Forward-Looking Statements and Non-GAAP Financial Information Forward-Looking Statements Information in this presentation or in oral statements of the management of the Company may include forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. You can identify these statements by our use of such words as "will," "g ...

NASDAQ: HBIO Q1'22 Earnings Presentation Jim Green, Chairman, President & CEO Mike Rossi, CFO May 4, 2022 Forward-Looking Statements and Non-GAAP Financial Information Forward-Looking Statements Information in this presentation or in oral statements of the management of the Company may include forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. You can identify these statements by our use of such words as "will," "guid ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2022 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from_____to _____ (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Commission file number 001-33957 HARVARD BIOSCIE ...

Harvard Bioscience, Inc. (NASDAQ:HBIO) Q1 2022 Earnings Conference Call May 4, 2022 8:00 AM ET Company Participants David Sirois - Director of Corporate Accounting & SEC Reporting James Green - President & Chief Executive Officer Michael Rossi - Chief Financial Officer Conference Call Participants Paul Knight - KeyBanc Capital Markets Tim Chiang - Northland Capital Markets Bruce Jackson - The Benchmark Company Operator Good morning, ladies and gentlemen. Thank you for standing by and welcome to the Harvard ...